Want to see SRZN full AI Analyst Report?
SRZN Stock Chart & Stats
$23.36
-$0.60(-3.04%)
At close: 4:00 PM EDT
$23.36
-$0.60(-3.04%)
Day’s Range― - ―
52-Week Range$11.25 - $35.00
Previous CloseN/A
Volume104.46K
Average Volume (3M)25.24K
Market Cap
$263.51M
Enterprise Value$504.92
Total Cash (Recent Filing)$102.04M
Total Debt (Recent Filing)$6.32M
Price to Earnings (P/E)―
Beta-0.22
Next Earnings
Nov 11, 2026EPS Estimate
-1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.13
Shares Outstanding11,753,558
10 Day Avg. Volume29,706
30 Day Avg. Volume25,240
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.90
Price to Sales (P/S)48.61
P/FCF Ratio-5.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$44.60Price Target Upside90.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-6.81
Revenue Forecast (FY)$10.93M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe strong TTM revenue rebound indicates improved funding or collaboration activity after a weak period. Sustaining this recovery could support continued development investment, although the company remains dependent on non-commercial revenue sources.
High Gross MarginA very high gross margin suggests reported revenue carries limited direct delivery costs, which could provide attractive operating leverage if revenue scales. The benefit is currently offset by substantial research and operating expenses.
Focused Regenerative Medicine PlatformA focused Wnt-based platform gives Surrozen a coherent scientific strategy across epithelial tissue diseases. Success in one indication could potentially support expansion into related disorders, though clinical validation remains necessary.
Bears Say
Extreme Net LossesThe loss level is disproportionate to current revenue and shows that Surrozen’s cost base is not yet supported by operations. Continued heavy spending raises the need for successful clinical outcomes, cost reduction, or additional financing.
Persistent Cash BurnNegative operating and free cash flow indicate the company is not self-funding its research programs. Ongoing development spending will likely require external capital, creating liquidity exposure and potential shareholder dilution.
Negative Shareholders’ EquitySustained negative equity reflects a sharp deterioration in balance-sheet quality and limits financial flexibility. Even with modest absolute debt, the capital structure increases dependence on financing and heightens dilution or restructuring risk.
Surrozen News
SRZN FAQ
What was Surrozen’s price range in the past 12 months?
Surrozen lowest stock price was $11.25 and its highest was $35.00 in the past 12 months.
What is Surrozen’s market cap?
Surrozen’s market cap is $263.51M.
When is Surrozen’s upcoming earnings report date?
Surrozen’s upcoming earnings report date is Nov 11, 2026 which is in 71 days.
How were Surrozen’s earnings last quarter?
Surrozen released its earnings results on Aug 06, 2026. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$1.288 by $0.878.
Is Surrozen overvalued?
According to Wall Street analysts Surrozen’s price is currently Undervalued.
Does Surrozen pay dividends?
Surrozen does not currently pay dividends.
What is Surrozen’s EPS estimate?
Surrozen’s EPS estimate is -1.1.
How many shares outstanding does Surrozen have?
Surrozen has 11,753,558 shares outstanding.
What happened to Surrozen’s price movement after its last earnings report?
Surrozen reported an EPS of -$0.41 in its last earnings report, beating expectations of -$1.288. Following the earnings report the stock price went up 18.392%.
Which hedge fund is a major shareholder of Surrozen?
Currently, no hedge funds are holding shares in SRZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Surrozen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.60 (90.92% Upside)
$44.60 (90.92% Upside)
Blogger Sentiment
Bullish
SRZN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 56.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 28.3%
Last 30 Days ▼ 28.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Surrozen
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
SRZN Stock 12 Month Forecast
Average Price Target
$44.60
▲(90.92% Upside)
Technical Analysis
Opus Genetics
―
Ovid Therapeutics
―
Shattuck Labs
―
Spruce Biosciences
―
Biomea Fusion
―
Ownership Overview
43.85% Insiders
1.87% Mutual Funds
5.73% Other Institutional Investors
42.35% Public Companies and
Individual Investors